Mothers against decapentaplegic homolog 4
From Wikipedia, the free encyclopedia
 |
The introduction to this November 2006 provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
SMAD4 (also known as DPC4 or Mothers against decapentaplegic homolog 4) is a 552 amino acid polypeptide involved in cell signaling. It belongs to the Darfwin family of proteins which modulate members of the TGFβ protein superfamily. It binds receptor regulated SMADs such as SMAD1 or SMAD2 and forms a complex that binds to DNA and serves as a transcription factor. It is the only known mammalian coSMAD. It is a homolog of the Drosophila protein: "Mothers against decapentaplegic".
Contents |
[edit] Nomenclature
The SMAD proteins are homologs of both the drosophila protein, mothers against decapentaplegic (MAD) and the C. elegans protein SMA. The name is a combination of the two. During Drosophila research, it was found that a mutation in the gene, MAD, in the mother, repressed the gene, decapentaplegic, in the embryo. The phrase "Mothers against" was added since mothers often form organizations opposing various issues eg. Mothers Against Drunk Driving or (MADD).
[edit] Structure
SMADs are highly conserved across species, especially in the N terminal MH1 domain and the C terminal MH2 domain. The MH1 domain has DNA specific binding properties, where it binds to specific nucleotide sequences. It also facilitates the binding of SMAD4 to the phosphorylated C-terminus of R-SMADs. The MH2 domain is responsible for receptor recognition and oligomerization with other SMADs as well as DNA binding. The MH2 domain directly interacts with the MH1 domain of R-SMADs.[1]
[edit] Function
SMAD4 binds to receptor regulated SMADs (R-SMADs), such as SMAD1 or SMAD2 and facilitates the translocation of the heteromeric complex into the nucleus. SMAD4 may form heterotrimeric, heterohexameric or heterodimeric complexes with R-SMADs.
In the nucleus the heteromeric complex binds promoters and interact with transcriptional activators. SMAD3/SMAD4 complexes can directly bind the SBE (Smad-binding DNA element) which is a four base pair sequence 5′-GTCT-3' or the complement 5′-AGAC-3′.[2] These associations are weak and require additional transcription factors such as members of the AP-1 family, TFE3 and FoxG1 to regulate gene expression.[2]
Many TGFβ ligands use this pathway and subsequently SMAD4 is involved in many cell functions such as differentiation, apoptosis, gastrulation, embryonic development and the cell cycle.
[edit] Disease
SMAD4, is often found mutated in many cancers. SMAD4 alterations have been found in multiploid colorectal cancer and pancreatic carcinoma. It is found inactivated in at least 50% of pancreatic cancers[3]. It is also found mutated in the autosomal dominant disease juvenile polyposis syndrome (JPS). JPS is characterized by characterized by hamartomatous polyps in the gastrointestinal (GI) tract. These polyps are usually benign, however they are at greater risk of developing gastrointestinal cancers, in particular colon cancer.
Somatic mutations found in human cancers of the MH1 domain of Smad4 have been shown to inhibit the DNA-binding function of this domain.
[edit] References
- ^ "Phosphorylation of threonine 276 in Smad4 is involved in transforming growth factor-beta-induced nuclear accumulation" (Oct 2003). Am J Physiol Cell Physiol.. Entrez PubMed 12801888 12801888.
- ^ a b Inman, Gareth J. (Feb 2005). "Linking Smads and transcriptional activation". Biochem J.. PMID 15702493. Entrez PubMed 15702493 15702493.
- ^ Kumar; Abbas & Fausto (July 30). in 7th edition: Robbins & Cotran's Pathologic Basis of Disease. Saunders. ISBN 0721601871.
|
||||||||||||||||||||
